Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shot up 4.3% on Monday . The company traded as high as $422.47 and last traded at $421.60, with a volume of 567,128 shares changing hands. The stock had previously closed at $404.30.

A number of research firms have weighed in on REGN. Vetr raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.09 price objective on the stock in a report on Tuesday, August 2nd. Canaccord Genuity reaffirmed a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Robert W. Baird downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $505.00 to $448.00 in a report on Friday, August 5th. Cowen and Company reaffirmed a “hold” rating and set a $430.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Finally, Roth Capital reissued a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and thirteen have assigned a buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average price target of $477.00.

The company has a 50-day moving average price of $401.82 and a 200 day moving average price of $388.36. The firm has a market cap of $44.36 billion and a P/E ratio of 66.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.17. During the same quarter in the previous year, the company posted $2.89 earnings per share. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.24 billion. The business’s quarterly revenue was up 21.4% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals Inc. will post $10.95 EPS for the current year.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the sale, the director now directly owns 15,125 shares in the company, valued at approximately $6,428,125. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sanofi purchased 64,731 shares of the company’s stock in a transaction that occurred on Tuesday, June 14th. The shares were acquired at an average price of $363.86 per share, for a total transaction of $23,553,021.66. The disclosure for this purchase can be found here.

A number of hedge funds have recently bought and sold shares of REGN. Schwab Charles Investment Management Inc. raised its stake in Regeneron Pharmaceuticals by 16.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 218,216 shares of the biopharmaceutical company’s stock worth $118,463,000 after buying an additional 31,441 shares during the period. KBC Group NV raised its stake in Regeneron Pharmaceuticals by 13.8% in the fourth quarter. KBC Group NV now owns 14,604 shares of the biopharmaceutical company’s stock worth $7,928,000 after buying an additional 1,767 shares during the period. Victory Capital Management Inc. raised its stake in Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 1,067 shares during the period. Calvert Investment Management Inc. raised its stake in Regeneron Pharmaceuticals by 26.4% in the fourth quarter. Calvert Investment Management Inc. now owns 4,027 shares of the biopharmaceutical company’s stock worth $2,186,000 after buying an additional 840 shares during the period. Finally, I.G. Investment Management LTD. raised its stake in Regeneron Pharmaceuticals by 1.3% in the fourth quarter. I.G. Investment Management LTD. now owns 20,090 shares of the biopharmaceutical company’s stock worth $10,906,000 after buying an additional 264 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.